Sepetaprost
As of the edition of 20 October 2026, Sepetaprost is a small molecule: marketed, first approved in 2025 (JP); acts on PTGER3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Setaneo
- First approved
- 25 August 2025 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Santen Pharmaceutical
- Registered trials
- 8, 0 stopped early
- Disease areas
- Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGER3 | Prostaglandin E2 receptor EP3 subtype | P43115 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Santen Pharmaceutical | Applicant and Lead sponsor of trials | 2017 to now |